RNS & Investor News


17 December Directorate Change
Appointment of Managing Director of OptiBiotix's prebiotic division
14 December Issue of Convertible Loan Notes by ProBiotix and
Related Party Transaction
05 December Holding(s) in Company
04 December SlimBiome® Medical agreement for Greece and Cyprus
29 November SlimBiome Medical Exclusive Manufacturing Agreement
27 November SlimBiome® granted medical device status and CE mark
22 November CholBiome® agreement for Greece and Cyprus
11 October Director's dealing
09 October OptiBiotix Health signs manufacturing and supply agreement with US Pharma Lab
proactiveinvestors (website)
09 October LPLDL® US manufacturing and supply agreement
08 October Exercise of Options, Director's Dealing and Issue of Equity
03 October Non-exclusive distribution agreement for SlimBiome®
01 October Non-exclusive distribution agreement for SlimBiome®
26 September OptiBiotix looking to spin-out divisions to commercialise technologies
YouTube (website)
26 September Distribution agreement for cholesterol reducing CholBiome®
25 September Grant of Options
PDMR Dealing
24 September Formation of ProBiotix Health Limited
Appointment of Adam Reynolds as Chairman
10 September Director Appointment
10 September Exercise of Warrants and Issue of Equity
10 September Licence agreement with Bened Biomedical
05 September US deal launches OptiBiotix's LPLDL probiotic into huge pharma space
proactiveinvestors (website)
04 September OptiBiotix signs US pharmaceutical deal
for its cholesterol reducing Lactobacillus plantarum strain
30 August Half Yearly Report
22 August OptiBiotix Health sees revenues build as agreements turn into commercial deals
proactiveinvestors (website)
31 July Director's dealing
19 July Optibiotix is a very clever business model says chairman
YouTube (website)
17 July Investors 'beginning to realise the potential' in OptiBiotix Health - CEO
proactiveinvestors (website)
17 July Grant of Options
12 July Director's dealing
06 July Holding(s) in Company
04 July Result of AGM
04 July Directorate change
26 June Agreement with global corporate for SweetBiotix®
21 June Exclusive license agreement for LPLDL®
18 June Manufacturing, supply and profit sharing agreement with Morley Foods
14 June Exercise of Options and Issue of Equity
11 June Notice of AGM
07 June US launch of LPLDL® with Seed Health
31 May SweetBiotix®: Evaluation agreement with global dairy company
30 May Placing and Issue of Equity
23 May Final Results
22 May LP-LDL® agreement for USA
18 May SlimBiome® wins award at Vitafoods 2018
16 May Holding(s) in Company
16 May Exclusive manufacturing and supply agreement
08 May Launch of extended range of LPLDL® and SlimBiome® products at Vitafoods 2018
01 May LP-LDL® news media interest in USA
30 April Notice of Results
24 April Non-Exclusive UK distribution agreement for SlimBiome®
19 April Appointment of Head of Online Sales and Marketing
18 April Exclusive distribution agreement with Trigen Pharma for CholBiome®
05 April New patent filings: SweetBiotix®
03 April SkinBiotherapeutics (of which OptiBiotix owns 42%) announces the signing of a Material Transfer Agreement with a major global consumer goods company
proactiveinvestors (website)
27 March Scientific and commercial update
08 March Launch of Slimbiome® in Nutri-bites®
06 March LPLDL® Exclusive European License Agreement
28 February OptiBiotix Capital Reorganisation
06 February Exercise of warrant and issue of equity
01 February Director's dealing
30 January Exercise of warrant and issue of equity
25 January Result of GM
23 January SweetBiotix® development: Results of further human taste studies
17 January Presentation of research data at European Conference: ProBiota 2018
08 January Shareholder Circular and Notice of General Meeting
08 January Directorate changes